Convalescent Plasma
/ Ahvaz Jundishapur University of Medical Sciences
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
May 13, 2024
The Effects of Convalescent Plasma Transfusion on Serum Levels of Macrophage-Associated Inflammatory Biomarkers in Patients with Severe COVID-19.
(PubMed, J Interferon Cytokine Res)
- "In addition, real-time PCR data analyses showed that the relative expression of NF-κB2 was significantly declined in the patients who received plasma. The use of convalescent plasma probably has a significant inhibitory effect on the cytokines, chemokines, and inflammatory genes related to macrophage activation, which are closely associated with the worsening of clinical outcomes in severe COVID-19."
Biomarker • Journal • Infectious Disease • Inflammation • Novel Coronavirus Disease • Oncology • Respiratory Diseases • CCL3 • IL6 • TNFA • TXNIP
November 24, 2021
Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials.
(PubMed, BMC Infect Dis)
- "Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care."
Clinical • Journal • Retrospective data • Review • Critical care • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
April 11, 2021
A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm.
(PubMed, Intern Emerg Med)
- "The length of in-hospital stay, and mortality rate did not significantly reduce in the CP group compared with controls (p > 0.05) while WHO severity scores remarkably improved (p = 0.01), despite the higher frequency of underlying diseases among the CP group (66.7%) vs. controls (33.3%). Although CP has a remarkable immunomodulatory and antiviral potential to improve the cytokine storm and disease severity in COVID-19 patients, it did not considerably affect the mortality rate."
Clinical • Cytokine storm • Journal • Immune Modulation • Infectious Disease • Inflammation • Novel Coronavirus Disease • IFNG • IL10 • IL6 • TNFA
1 to 3
Of
3
Go to page
1